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The structure, complementary structure and cytogenetic/prolifera-
tive effects of the Met-enkephalin on human peripheral blood lym-
phocytes were analyzed. Met-enkephalin, i.e. Peptid-M (LUPEX®),
is a low molecular weight synthetic pentapeptide that corresponds
to thymus Met-enkephalin. Its structure was examined by means
of NMR spectroscopy. The influence of Met-enkephalin on in vitro
normalization of chromosomally aberrant lymphocytes of patients
suffering from different immune-mediated diseases, was analyzed
by the sensitive cytogenetic tests for screening and detection of ge-
nome damages in human lymphocytes. The tests showed that in vi-
tro stimulation of human lymphocytes with the Met-enkephalin led
to dissapearance of different types of chromosome aberrations, re-
duction in the number of micronuclei, decrease in the frequency of
sister chromatid exchange (SCE) and apoptosis as well as a cyto-
static effect on mitosis cycles. They have also confirmed normaliza-
tion of chromosomally aberrant cell findings in patients suffering
from different immune-mediated diseases. These results suggest a
possible role of Met-enkephalin (Peptid-M) in immunotherapy of
different diseases which involve chromosomal aberrations as well
as abnormal cell proliferation and offer new approaches to immu-
notherapy by the use of Peptid-M. Based on the molecular recogni-
tion theory and the SCA method, peptide complementary to Peptid-M
was designed, synthesized and denoted Peptide-D. Peptide-D is a
calpastatin fragment. Predicted ligand-receptor interaction between
both peptides is confirmed by the results showing that Peptide-D
blocked the Peptid-M induced lymphocyte proliferation in a dose-
dependent manner.
INTRODUCTION
In human lymphocytes, gene mutation occurs mostly in dividing cells.
Aberrant lymphocyte clones, stimulated by autoantigens have been isolated
from subjects with different immune-mediated diseases.1–6 Mutant oligo-
clonal T and B cell clones are thought to be involved in the production of oli-
goclonal immunoglobulins, i.e. antibodies of restricted clonal heterogeneity,
often directed to self-antigens (e.g. retinal S-antigen, myelin basic protein,
etc.).1–3,7–10
Chromosomal investigations of peripheral blood lymphocytes (PBL) in
multiple sclerosis (MS), uveitis and other autoimmune diseases revealed
different aberrations, particularly chromosomal breaks.1–6 Cytogenetic data
also showed that chromosome abnormalities were more common in subjects
with a high frequency of relapse or with a progressive form of the disease.6
In recent years, new approaches to the treatment of immune-mediated dis-
eases have been considered. Some of them include administration of low mo-
lecular substances, e.g. peptides, and their effects on cell cycle, cytokine se-
cretion and apoptosis.2,3,7–9,10
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Met-enkephalin, i.e. Peptid-M (LUPEX®), is an ubiquitous pentapeptide
found in different tissues, including thymus.2,3,11–16 Recent reports indicate
that it may be a promising new drug for several immune-mediated diseas-
es.2,3,11–13 It was also shown that Peptid-M modulates lymphocyte2,3 and
other tissues14–16 cell cycle, and protects cells against chromosomal aberra-
tions in vitro and in vivo.2,3
The aim of this study was to investigate in vitro effects of Met-enke-
phalin (Peptid-M) on the number and types of lymphocyte cromosomal aber-
rations, cell cycle and apoptosis in subjects suffering from immune-mediat-
ed diseases. We also analyzed the structure of Peptid-M by means of NMR
spectroscopy. To obtain more data on the effector function of Peptid-M and
its interaction with other receptor systems we observed the effects of
Peptid-M and its receptor site on lymphocyte proliferation. The receptor site
of Peptid-M was recently defined by Štambuk17,18 according to the molecu-
lar recognition theory.17–22
MATERIAL AND METHODS
Peptid-M Analysis
Syntethic analogue of thymus Met-enkephalin, i.e. Peptid-M (LUPEX®,
Biofactor, Germany) was analyzed by one- and two-dimensional NMR spec-
troscopy on a Varian Gemini 300 spectrometer, operating at 75.46 MHz for
the 13C nucleus. The samples were dissolved in DMSO-d6 solution at 20 °C
and recorded in 5 mm NMR tubes. Chemical shifts were referred to TMS.
Digital resolution in 1H NMR spectra was 0.28 Hz per point and 0.70 Hz per
point in 13C NMR spectra. The techniques used were: broadband proton de-
coupling, gated decoupling, APT, COSY, NOESY and HETCOR. COSY spec-
tra were obtained in magnitude mode, while NOESY spectra in phase-
sensitive mode. In both, COSY and NOESY, 1024 points in F2 dimension
and 256 increments in F1 dimension were used. Data in F1 were subse-
quently zero-filled to 1024 points. Every increment was obtained with 16
scans, using a 2750 Hz spectral width and a relaxation delay of 1 s. The
resolution was 5.4 Hz/point and 10.7 Hz/point in F2 and F1 dimensions, re-
spectively. NOESY spectra were measured with several mixing times
(0.45–0.70 s). HETCOR spectra were obtained with 2048 points in F2 di-
mension and 256 increments in F1 dimension, which were zero-filled to 512
points. The increment parameters were as follows: 64 scans, relaxation de-
lay of 1 s, spectral width of 20000 Hz in F2 and 4500 Hz in F1 dimensions.
Digital resolution was 19.53 Hz/point in F2 and 17.6 Hz/point in F1 dimen-
sion. Proton decoupling was performed by Waltz-16 modulation. Standard
one- and two-dimensional pulse sequences were used.
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Defining and Synthesis of Peptide-D
The sequence of Peptide-D (IPPKY), complementary to Peptid-M
(YGGFM), was derived by Štambuk by means of the SCA procedure based
on the molecular recognition theory.17–19 Briefly, the method defines the
most probable complementary pairs that interact, based on the analyses of
a large number of complementary motifs belonging to seven different
ligand-receptor systems (epidermal growth factor, interleukin 2, transferrin,
von Willebrand factor, angiotensin II/III, vitronectin and prolactin).17,18
Peptide-D was synthesized using the standard solid-phase method and ana-
lyzed by HPLC and amino acid analysis (Biofactor, Germany; Lot No. B-
0158). Synthesized Peptide-D had a molecular mass of 616.8 D, sequence
H-Ile-Pro-Pro-Lys-Tyr-OH, and >97% purity.
Sample Collection
Samples of venous blood for the in vitro study of PBL were obtained
from 22 subjects (17F/5M) suffering from ocular, demyelinating, rheumatic
and allergic autoimmune diseases and type I diabetes (3 intermediate uvei-
tis, 2 optic neuritis and multiple sclerosis, 1 hereditary eosinophilia with
front eye segment affections, 1 neurodermitis with keratoconus and atopy, 1
Fuchs' cyclitis with subacute sclerosing panencephalitis, 10 diabetic retino-
pathy, 4 rheumatoid arthritis). Lymphocytes were cultivated in vitro. For
each culture heparinized whole blood was added to F-10 medium (Sigma),
supplemented with fetal bovine serum, phytohaemagglutinin (Murex) and
antibiotics (penicillin and streptomycin). While conducting the investiga-
tion, the principles of Helsinki Declaration were observed.
Peptid-M Effects on Cytogenetic Findings
Cytogenetic tests of structural chromosome analysis (CA), sister chro-
matid exchange (SCE) and micronucleus (MN) assay were carried out in the
control and Peptid-M treated cultures (Figures 2 and 3) to determine the
mutagenic status in vitro before and after lymphocyte stimulation with
Peptid-M (LUPEX®). In Peptid-M treated cultures, standard assays22–26
were modified with 1.2 g/mL of its aqueous solution for each method, as de-
scribed by Štambuk et al.2,3
Analysis of Chromosome Aberrations
Lymphocytes were cultivated for 48 h at 37 °C. In each culture, colchi-
cine was added 3 h before harvesting. Cultures were harvested and slides
were prepared according to the standard method.22 For hypotonic treat-
ment, 0.075 M potassium chloride was used, and for fixation, cold freshly
prepared fixative methanol/acetic acid (3:1). Cell suspensions were dropped
onto clean dry-cold slides. They were allowed to air-dry and were stained
594 N. [TAMBUK ET AL.
with 5% Giemsa solution. For structural chromosome aberrations, 300 well
spread metaphases for each culture were examined. Cells were analyzed for
chromatid and chromosome breaks, acentric fragments, dicentric and ring
chromosomes.
Sister Chromatid Exchange Analysis
For SCE analysis and studies of cell proliferation, 5-bromodeoxyuridine
(BrdU) was added to cultures at the initiation of the experiment and cells
were cultivated for 72 h. These cultures were shielded from light. For mi-
totic arrest, colhicine was added to each culture 3 h before harvest. Slides
were prepared according to the standard method.23 SCE were analyzed in
50 second division cells for each sample, and the proportion of first, second
and third mitoses was based on 300 metaphases per experimental point. To
define the cellular kinetics, the number of first (M1), second (M2), third and
more (M3) mitosis were investigated using SCE analysis and proliferation
rate indices (PRI).24,25
Micronucleus Evaluation
For the MN assay, the cells were cultivated for 72 h and cytohalasin B
(Sigma) was added to the cultures 28 h prior to harvesting, according to the
method described by Fenech and Morley.26 In order to preserve the cyto-
plasm, binucleated cells were not exposed to hypotonic treatment. Cells
were fixed with methanol/acetic acid (3:1). The slides were air-dried and
stained with 5% Giemsa solution. Scoring of MN was limited to binucleated
lymphocytes only with the preserved cytoplasm. The results are expressed
as the number and the distribution of micronuclei per 1000 binucleated
cells.
Peptid-M Effects on Cell Apoptosis
The level of lymphocyte apoptosis was evaluated in the cells of patients
with diabetic retinopathy. The results were obtained by comparing lympho-
cyte apoptosis in the Peptid-M treated and untreated 5-day cell cultures. Af-
ter a 5-day culture period, the cells were stained with propidium iodide (dead
cells) and fluorescein diacetate (viable cells) and apoptosis was counted and
evaluated using fluorescence microscopy at 490 nm as described by London
et al.27–29
Peptid-M Effects on Cell Proliferation
Lymphocyte proliferation was also performed by means of 5-day cell cul-
tures (sodium citrate anticoagulant, 2  105 cells/250 L well, 5% FCS) and
3H-Thymidine incorporation, as described by deSmet et al.30 Cellular prolif-
erative responses of the untreated, Peptid-M and Peptide-D treated cultures
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were compared. Blocking of Peptid-M induced lymphocyte proliferation by
means of different concentrations of its complementary Peptide-D is pre-
sented in Figure 4.
Statistical methods: Data were compared by the McNemar chi-square
test.
RESULTS
NMR Spectroscopy
NMR spectroscopy confirmed that the structure of synthetic Peptid-M
(LUPEX®, Biofactor, Germany) corresponds to Met-enkephalin. This analy-
sis was based on chemical shifts, spin-spin coupling constants and connec-
tivities in one and two-dimensional spectra. The assignment of signals was
substantiated by heteronuclear 1H–13C correlated two-dimensional meas-
urements (HETCOR). In dimethylsulfoxide solution (DMSO), Peptid-M
molecule exists in dipolar form. In Figure 1, the COSY spectrum of
Peptid-M in DMSO solution is given. Two- and three-bond spin-spin cou-
pling connectivities between amid and methine and/or methylene protons
corroborate dipolar structure. The amid proton signal of Phe4 is separated
from the signal of Gly,3 which is, in turn, overlapped with the amid proton
signal of Met5. In contrast, in the cationic form of Peptid-M, the Gly3 and
Phe4 amid signals would be overlapped, while amid proton signal of Met5
would be separated.31, 32
Effects on Cromosome Aberration, SCE and Micronuclei
Structural chromosome aberrations observed in lymphocytes of all sub-
jects before treatment with Peptid-M (LUPEX®) were chromatid breaks,
chromosome breaks, acentric fragments, dicentric and ring chromosomes
(Figure 2). The types and frequency of total chromosomal aberrations sig-
nificantly decreased after treatment with Peptid-M in all subjects (Figure
2a, p = 0.0027). Severe chromosome aberrations, i.e. dicentric (3) and ring
chromosomes (2), observed before treatment, disappeared after in vitro
stimulation with Peptid-M.
The data on the frequency of SCE are given in Figure 2b. In vitro stimu-
lation with Peptid-M caused a reduction of SCE frequencies per cell, as well
as a decline in the SCE range (Figure 2b, p < 0.001).
After in vitro stimulation with Peptid-M, the total number of micronu-
clei significantly decreased in all cell cultures (Figure 2c, p < 0.0001). Distri-
bution of micronuclei per 1000 binucleated cells was also changed, as com-
pared to untreated lymphocytes. We observed mainly binucleated cells with
one micronucleus in the Peptid-M treated cells, since the distribution of mi-
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cronuclei was shifted towards normalization, when compared to the un-
treated control samples of the same subjects (Table I, p < 0.0001).
Effects on Cell Cycle and Cell Apoptosis
Cell kinetics was examined following three cell cycles, the first (M1),
second (M2) and third (M3) mitosis in lymphocyte proliferation. After in vi-
tro treatment with Peptid-M, we observed a significant reduction in the
number of cells that reached the third or more metaphase (M3; Figure 3c, p
< 0.0011) and a significant increase in the number of first metaphase (M1;
Figure 3a, p < 0.0001). The number of cells im second mitotic division re-
mained the same (M2; Figure 3b, p = 0.5829). Decreased mitotic indices and
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Figure 1. The COSY spectrum of synthetic Met-enkephalin (Peptid-M) measured in
DMSO solution.
previously mentioned mitosis division findings confirmed suppressive ef-
fects of Peptid-M on mitotic activity in vitro.
The results presented in Figure 4 show that apoptosis was significantly
reduced in the Peptid-M treated lymphocyte cultures (2.9  1.1%) when
598 N. [TAMBUK ET AL.
Figure 2. (a) Chromosomal aberrations, (b) sister chromatid exchange and (c) micro-
nuclei in the control and Peptid-M (Met-enkephalin) treated cells.
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TABLE I
Peptid-M (Met-enkephalin) treated cell cultures show significantly less
micronuclei and a shift towards normalization in contrast to the control
untreated samples of the same subjects
No. micronuclei 0 1 2 3
Observed (Peptid-M treated)* 6444 54 1 0
Expected (From control values) 6377 118 4 0
*2 = 37.66; p < 0.0001 (Poisson distribution)
Figure 3. Number of cells in the first (a), second (b) and third (c) mitotic division in
the control and Peptid-M (Met-enkephalin) treated cells.
compared to the untreated control cultures (7.7  2.1%; p < 0.01) of the same
samples.
Evaluation of Ligand-Receptor Interaction
Ligand-receptor interaction between Peptid-M and its complementary
Peptide-D is presented in Figure 5b. It was detected by means of cellular
proliferative bioassay based on 3H-Thymidine DNA incorporation. Pept-
ide-D blocked Peptid-M, i.e. Met-enkephalin, induced lymphocyte prolifera-
tion in a dose-dependent manner (Figure 5b), and exhibited suppressive ef-
fects on cell proliferation in a low concentration range.
DISCUSSION
Immune-mediated and other diseases may be accompanied by chromo-
somal rearangements and aberrations.1–3 Chromosomal investigations car-
ried out on peripheral blood lymphocytes of subjects suffering from multiple
sclerosis and other severe diseases revealed different structural aberra-
tions, particularly chromosomal breaks, whose frequencies were significan-
tly higher than in healthy persons.4 Our results indicate that cytogenetic
tests are sensitive methods for the screening and detection of genome dam-
ages in human lymphocytes obtained from the subjects suffering form dif-
ferent ocular and other immune-mediated diseases.
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Figure 4. Apoptosis in the control and Peptid-M (Met-enkephalin) treated lympho-
cytes.
Met-enkephalin (Peptid-M) induced modulation of the cell cycle, its cy-
tostatic effects with prevention of mutations, and reduction of apoptosis
(programmed cell death) suggest possible applications of this pentapeptide
in different diseases which involve lymphocyte dysfunctions, chromosomal
aberrations and/or abnormal lymphocyte proliferation. In vitro disappear-
ence of abnormal lymphocyte clones in Figure 2 during Met-enkephalin
(Peptid-M) treatment has also been confirmed by a recent study of Štambuk
et al.3 reporting in vivo disappearance of mutant peripheral blood lympho-
cytes after Peptid-M immunotherapy in an 11-year-old girl.3,11,33 The latter
is to our knowledge the first report indicating that selection of white blood
cells may be therapeutically programmed with short peptides.3,11,33 It re-
mains to be determined if this also holds for other cells types.
CYTOGENETIC EFFECTS OF MET-ENKEPHALIN 601
Figure 5. (a) Proliferation of the control and Peptide-D treated lymphocytes. (b) Ef-
fects of Peptide-D on the Peptid-M (MENK) induced cell proliferation.
The effects of Met-enkephalin (Peptid-M) on cell apoptosis presented in
Figure 4 may be explained by the fact that its YGG sequence, which is a
part of the calmodulin-binding apoptosis associated protein kinase
(DAPK_HUMAN, 1127-1129 aa) binds to the sequences IPP and MPP1,7,18
belonging to the cellular apoptosis susceptibility protein CAS_HUMAN
(758–760 aa). In this way, both apoptotic pathways in proliferating lympho-
cytes treated with Met-enkephalin (Peptid-M) are disturbed and apoptosis
in proliferating lymphocytes may be supressed (Figure 4) regardless of the
cytostatic effects of the peptide on the mitosis cycle (Figure 3a–c). The ob-
servation of reduced apoptosis in normal lymphocytes is in line with the fact
that suppressive effects of Met-enkephalin (Peptid-M) on cell cycle do not
result in lymphopenia in vivo.10–13
Peptide-D is a complementary transcript of met-enkephalin, i.e. its pos-
sible receptor.17,18,34 It does not seem to exhibit acute toxicity in vivo since
its application in 1 g/kg and 10 g/kg doses (–30 min) did not induce toxic-
ity or changes of the lesions when compared to the untreated controls in the
standard rat cysteamine model (400 mg/kg cysteamine i.p., 0 min; strain:
Wistar, F).35 Theoretically predicted ligand-receptor interaction of Met-
enkephalin (Peptid-M) and peptide-D was based on the molecular recogni-
tion theory. 17,18,34 Similar results have been obtained by several authors for
different short peptide motifs and DNA/RNA transcripts.1,8–13 Results pre-
sented in Figure 5 confirm that Met-enkephalin (Peptid-M) receptors may
correspond to human calpastatin location (ICAL_HUMAN, residues 201–
205). This short peptide sequence represents the core of the septapeptide
TIPPKYR, which is a central conserved sequence generally associated with
the inhibitory activity of calpastatin.36,37 The latter also indicates that im-
munopathologic mechanisms related to the Met-enkephalin-opioid receptors
and calpain-calpastatin system may interact (and interfere), especially
since we measured specific and dose-dependent neutralization of the Met-
enkephalin (Peptid-M) induced lymphocyte proliferation with Peptide-D.
We additionally evaluated the Met-enkephalin (Peptid-M) induced ef-
fects on  and  opioid receptors13 in vivo by the Straub tail response38–40 in
mice (male NMRI, Pliva), in a dose of 1 mg/kg, which is therapeutically rele-
vant in animal and in human models.10,13 Since we could not detect signifi-
cant positive Met-enkephalin (Peptid-M) effects on the Straub tail behaviour,
which is thought to be the in vivo marker of the effects of the drug on  and
 opioid receptors, and we obtained a typical dose-response curve in the
Peptide-D neutralization of Met-enkephalin (Peptid-M) effects in bioassay
(Figure 5b), it is tempting to postulate that naloxone-dependent opioid
mechanism related to Met-enkephalin modulation may not neccessarily be
receptor specific.
Peptide-D sequence shares molecular homology to short sequences of
rapamycin-selective 25 kD immunophilin FKBP 25, i.e. Rapamycin and
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FK506 binding protein (FKB3_HUMAN, sequence PPKY, residues 108–111).
This explains the fact that immunosuppressive effects of Met-enkephalin
(Peptid-M) on mitotic division and cell cycle2,3,11,33 may be reversed by short
peptides containing PPK sequence.3,11 The fact that the IPPK sequence of
Peptid-D corresponds also to the sequence of common cytokine receptor 
chain (CYRG_HUMAN, 335–338 aa), IL-8 receptor (IL8A_HUMAN) and
IL-2 receptor indicates that immunologic mechanisms of IL-2 and IL-4 in-
teraction through common cytokine  chain, may be responsible for a num-
ber of effects of both peptides on the immune system, as discussed by Štam-
buk.41 Results of Noguchi et al.42 recently confirmed the involvement of
common cytokine  chain in calpain-calpastatin system. Evaluation of inter-
actions between Met-enkephalin (Peptid-M) and calpastatin could be impor-
tant for drug design related to several immune-mediated, degenerative and
genetic diseases,34,36,37 including: cataract, uveitis, optic neuritis, multiple
sclerosis, Alzheimer's disease and rheumatoid arthritis.
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SA@ETAK
Citogenetski u~inci Met-enkefalina (Peptida-M) na ljudske limfocite
Nikola Štambuk, Nevenka Kopjar, Karmela Šentija, Vera Garaj-Vrhovac, Dra`en
Viki}-Topi}, Branka Maruši}-Della Marina, Vesna Brinar, Milica Trbojevi}-^epe,
Neven @arkovi}, Bo`idar ]urkovi}, Ður|a Babi}-Nagli}, Mirko Had`ija, Niko
Zurak, Zdravko Brzovi}, Roko Martini}, Vjera Štambuk, Paško Konjevoda, Nikola
Ugrinovi}, Ivana Pavli}-Renar, Zdenko Bi|in i Biserka Pokri}
Analizirani su gra|a, komplementarna gra|a i citogenetski/proliferativni u~inci
Met-enkefalina na limfocite iz periferne ljudske krvi. Met-enkefalin, odnosno Pep-
tid-M (LUPEX®), nisko je molekularni sintetski pentapeptid koji odgovara timusnom
Met-enkefalinu. Utjecaj Met-enkefalina na in vitro normalizaciju kromosomski abe-
rantnih limfocita bolesnika s raznim autoimunim bolestima ispitan je osjetljivim
citogenetskim testovima za pregled i otkrivanje ošte~enja na ljudskim limfocitima.
Testovi su pokazali da in vitro stimulacija ljudskih limfocita Met-enkefalinom dovodi
do nestajanja raznih oblika kromosomskih aberacija, smanjenja broja mikronukleu-
sa, smanjene u~estalosti sestrinskih kromatidnih izmjena i apoptoze te citostatskog
u~inka na diobene cikluse. Tako|er je potvr|eno da je došlo do normalizacije kro-
mosomski aberantnih stanica kod pacijenata s raznim autoimunim bolestima. Ovi
rezultati ukazuju na mogu}u ulogu Met-enkefalina (Peptida-M) u imunoterapiji raz-
nih bolesti kod kojih dolazi do kromosomskih aberacija kao i nenormalne stani~ne
proliferacije, a ujedno omogu}uju nove pristupe imunoterapiji Peptidom-M. Sukla-
dno teoriji molekularnog prepoznavanja i SCA metodi uobli~en je i sintetiziran pep-
tid, komplementaran Peptidu-M, koji je nazvan Peptid-D. Peptid-D je dio kalpasta-
tina. Pretpostavljena interakcija tipa ligand-receptor izme|u dva peptida potvr|ena
je rezultatima koji su pokazali da se, ovisno o dozi dodanog Peptida-D, smanjuje pro-
liferacije limfocita izazvana Peptidom-M.
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